Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Gilead Sciences Inc (GILD) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 95,410,160
  • Shares Outstanding, K 1,319,660
  • Annual Sales, $ 32,639 M
  • Annual Income, $ 18,108 M
  • 36-Month Beta 1.21
  • Price/Sales 2.92
  • Price/Book 5.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.93 +0.49%
on 12/05/16
80.00 -9.65%
on 11/10/16
-0.15 (-0.21%)
since 11/04/16
3-Month
71.39 +1.25%
on 11/04/16
82.07 -11.93%
on 09/20/16
-5.60 (-7.19%)
since 09/06/16
52-Week
71.39 +1.25%
on 11/04/16
104.79 -31.02%
on 12/17/15
-31.79 (-30.55%)
since 12/04/15

Most Recent Stories

More News
Twilio Inc. trade offers a 13.03% return in 141 days, or find similar option trades on Gilead Sciences, Energy Select Sector, Halliburton, and NVIDIA

InvestorsObserver issues critical PriceWatch Alerts for GILD, HAL, NVDA, TWLO, and XLE.

Is GILD Stock A Good Buy For Income Investors? Gilead Sciences, Inc.

Gilead Sciences, Inc. (NASDAQ:GILD) stock is a good buy for income investors as it is yielding 2.5% and dividends are likely to go up as the company has strong financials.

J&J (JNJ) Reportedly Approaches Actelion for Acquisition

Reportedly, Johnson & Johnson (JNJ) recently approached Swiss biotechnology company, Actelion Ltd. (ALIOF), with a potential takeover offer.

Galapagos (GLPG) Filgotinib in Phase III for Crohn's Disease

Galapagos (GLPG) dosed the first patient in the phase III DIVERSITY study on filgotinib for the treatment of Crohn's disease.

Gilead Sciences Canada, Inc., is awarded prestigious Prix Galien Canada Innovative Product Award

- HARVONI® for Chronic Hepatitis C Transforms Treatment and Increases Cure Rates for Patients with the Most Common Genotype of the Disease -

Biotech Stock Roundup: Acorda Stops Ampyra PSWD Development, CRL for Spectrum's Qapzola

Focus is back on pipeline and regulatory updates with the end of the third quarter earnings season and elections.

GILD Stock: The Rally In Gilead Sciences Inc (GILD) Stock Is Just Getting Started

Gilead Sciences, Inc. (NASDAQ:GILD) stock price didn't break down very much this time round even in the face of falling HCV sales.I still feel it has plenty more upside.

Gilead Reports Phase III Myelofibrosis Data on Momelotinib

Gilead Sciences (GILD) announced top-line data from two phase III studies on momelotinib in patients with myelofibrosis.

Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis

Gilead Sciences, Inc. (Nasdaq: GILD) today announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase...

Sell These 5 Stocks Now Before it’s Too Late

Each week Forcerank runs a variety of games covering different industries. What we have found, is that the lowest ranked companies in their respective games deliver the biggest negative price movement...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Gilead Sciences, Inc. is an independent biopharmaceutical company that seeks to provide accelerated solutions for patients and the people who care for them. They have a broad-based focus on developing and marketing drugs to treat patients with infectious diseases, including viral infections, fungal infections...

See More

Support & Resistance

2nd Resistance Point 73.46
1st Resistance Point 72.91
Last Price 72.29
1st Support Level 71.87
2nd Support Level 71.38

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.